Get the Stockscreener App
0.9761
3.50%
-0.0211
Promis Neurosciences Inc stock is traded at $0.9761, with a volume of 1,164.
It is down -3.50% in the last 24 hours and up +1.29% over the past month.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
See More
Previous Close:
$0.9972
Open:
$0.99
24h Volume:
1,164
Relative Volume:
0.02
Market Cap:
$32.60M
Revenue:
-
Net Income/Loss:
$-563.30K
P/E Ratio:
-0.3754
EPS:
-2.6
Net Cash Flow:
$-22.23M
1W Performance:
-3.23%
1M Performance:
+1.29%
6M Performance:
-47.41%
1Y Performance:
-26.74%
1-Day Range:
$0.95
$0.99
1-Week Range:
$0.91
$1.04
52-Week Range:
$0.91
$3.10
Promis Neurosciences Inc Stock (PMN) Company Profile
Name
Promis Neurosciences Inc
Sector
Industry
Phone
416-847-6898
Address
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| PMN | 0.9622 | 32.60M | 0 | -563.30K | -22.23M | -2.60 |
| VRTX | 447.38 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.51 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.80 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.60 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.76 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Promis Neurosciences Inc Stock (PMN) Latest News
ProMIS Neurosciences stock hits 52-week low at $0.91 - Investing.com
ProMIS Neurosciences stock hits 52-week low at $0.91 By Investing.com - Investing.com Australia
ProMIS Neurosciences Announces Third Quarter Financial Results and Recent HighlightsOn November 14, 2024, ProMIS Neurosciences Inc. (Nasdaq: PMN) shared its financial outcomes for the third quarter ended September 30, 2024. The company provide - Defense World
ProMIS Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
GREAT POINT PARTNERS LLC Acquires Shares in ProMIS Neurosciences Inc - GuruFocus.com
ProMIS Neurosciences Inc (PMN) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in ProMIS Neurosciences Inc - GuruFocus.com
ProMIS Neurosciences Inc Reports Q3 2024 GAAP EPS of $0.31, Surp - GuruFocus.com
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights - GlobeNewswire
ProMIS Reports Positive Phase 1a Results for Alzheimer's Drug, Secures $30.3M Financing | PMN Stock News - StockTitan
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference - GlobeNewswire
ProMIS Neurosciences (STU:23J0) PensionAndRetirementBenefit : €0.43 Mil (As of Jun. 2024) - GuruFocus.com
Biotech Shares Positive Phase I Data for Alzheimer's Treatment - Streetwise Reports
ProMIS Neurosciences Presents Positive Data from PMN310 - GlobeNewswire
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference - StockTitan
ProMIS Neurosciences, Inc. (NASDAQ:PMN): Among The 10 Oversold Canadian Stocks to Buy Right Now - Insider Monkey
ProMIS Neurosciences stock hits 52-week low at $0.92 - Investing.com India
ProMIS Neurosciences stock hits 52-week low at $0.92 By Investing.com - Investing.com South Africa
ProMIS Neurosciences, Inc. (PMN): Analysts Are Bullish On This Undervalued Canadian Stock Now - Insider Monkey
ProMIS Neurosciences appoints new CEO Neil Warma By Investing.com - Investing.com Australia
ProMIS Neurosciences appoints new CEO Neil Warma - Investing.com
ProMIS Neurosciences Names Neil Warma Permanent CEO - TipRanks
ProMIS Neurosciences (NASDAQ:PMN) versus Rigel Pharmaceuticals (NASDAQ:RIGL) Head-To-Head Analysis - Defense World
ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying - MSN
Director Madge Shafmaster Acquires 200,000 Shares of ProMIS Neur - GuruFocus.com
ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Madge K. Shafmaster Acquires 60,000 Shares - Defense World
ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Buys $89,600.00 in Stock - Defense World
ProMIS Neurosciences director Shafmaster purchases $255,750 in stock By Investing.com - Investing.com South Africa
ProMIS Neurosciences director Shafmaster purchases $255,750 in stock - Investing.com India
ProMIS Neurosciences (NASDAQ:PMN) versus Regulus Therapeutics (NASDAQ:RGLS) Critical Contrast - Defense World
BSE SME Popular Foundation slips on debut - Business Standard
Popular Foundations shares list at IPO price on BSE SME platform - The Economic Times
Popular Foundations makes tepid debut, shares list flat at ₹37 apiece on BSE SME platform - Upstox
How To Check Popular Foundations IPO Allotment Status - NDTV Profit
Taking a look at what insiders are doing to gauge the PureCycle Technologies Inc (PCT)’s direction - Knox Daily
Popular Foundations IPO allotment to be finalized today - IPO Watch
Prosperity Bancshares, Inc. (NYSE:PB) Shares Bought by Federated Hermes Inc. - Defense World
The Psychology of PureCycle Technologies Inc Inc. (PCT) Price Performance: Understanding Market Sentiment - The InvestChronicle
ProMIS Neurosciences to Showcase PMN310’s Ability to Target - GlobeNewswire
ProMIS unveils promising Alzheimer's antibody data at ICBN By Investing.com - Investing.com Australia
ProMIS unveils promising Alzheimer's antibody data at ICBN - Investing.com India
Pre-market Movers: TNON, FULC, SMFL, RYDE, NTGR… - RTTNews
ProMIS Neurosciences (NASDAQ:PMN) Trading Down 5% - Defense World
Promis Neurosciences Inc Stock (PMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):